Spirox

Provider of non-invasive treatment of nasal valve obstruction

placeMenlo Park, California, United States calendar_todayFounded 2013 groups50 employees language spiroxmed.com

Registered entities

Innovation

11 patent families (11 granted) — focus: Human necessities; filing pace steady. Cited 3,126 times.

YearFilings
20142
20162
20173
20187
20198
20206
20217
20223
20236
20248
20254

Investor mix

8 investors on record; lead investors include Venrock, Aisling Capital, KKR; 2 have since exited.

Investor typeCountShare
Venture capital450%
Private equity338%
Bank & private debt113%
Coming soon